Lycia Therapeutics CMO reports two stock option holdings

The awards vest in installments, with future vesting conditioned on Lee's service to Lycia on each vesting date.

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. Chief Medical Officer and 10% owner Chin Hyok Lee reported direct holdings of options to buy 366,402 common shares at an exercise price of $2.44, expiring February 12, 2035, and 73,191 common shares at $3.70, expiring August 10, 2036. As of October 22, 2026, the first award had vested as to 1/4, with an additional 1/48 of the total award to vest monthly; the second had vested as to 1/48, with an additional 1/48 to vest monthly. Both schedules are subject to Lee's service to Lycia on each vesting date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Lee Chin Hyok

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--
holding	Stock Option (Right to Buy) F2	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 439,593 contracts (Direct)

Footnotes (2)

1. F1. The options vested as to 1/4 of the total award on February 1, 2026, and an additional 1/48 of the total award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
2. F2. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Underlying common shares: 366,402 shares Exercise price: $2.44 per share Expiration date: February 12, 2035 +3 more

6 metrics

Underlying common shares 366,402 shares Options expiring February 12, 2035

Exercise price $2.44 per share Options expiring February 12, 2035

Expiration date February 12, 2035 Options covering 366,402 common shares

Underlying common shares 73,191 shares Options expiring August 10, 2036

Exercise price $3.70 per share Options expiring August 10, 2036

Expiration date August 10, 2036 Options covering 73,191 common shares

Key Terms

Stock Option (Right to Buy), exercise price, vest

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"an additional 1/48 of the total award will vest monthly thereafter"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LYCA options did Chief Medical Officer Chin Hyok Lee report?

Chin Hyok Lee reported direct options covering 366,402 common shares at a $2.44 exercise price and 73,191 common shares at a $3.70 exercise price. Their respective expiration dates are February 12, 2035, and August 10, 2036.

What is the vesting schedule for Chin Hyok Lee's LYCA options?

The 366,402-share award vested as to 1/4 on February 1, 2026, with an additional 1/48 of the total award to vest monthly thereafter. The 73,191-share award vested as to 1/48 on September 6, 2026, with an additional 1/48 to vest monthly thereafter. Both schedules are subject to Lee's service to Lycia on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/24/2026 - 08:14 PM EDT Accepted by SEC EDGAR 10/22/2026 - 07:13 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lee Chin Hyok

(Last) (First) (Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/22/2026

3. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	02/12/2035	Common Stock	366,402	$2.44	D
Stock Option (Right to Buy)	(2)	08/10/2036	Common Stock	73,191	$3.7	D

Explanation of Responses:

1. The options vested as to 1/4 of the total award on February 1, 2026, and an additional 1/48 of the total award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Amy Bachrodt, Attorney-in-Fact	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)